The FDA rebuked Baxter in a lengthy warning letter that outlined a series of production violations that led to a trio of ...

Delaying the use of subcutaneous Parkinson’s disease treatments by one year increases annual medical costs by 59.1%, ...

The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium | The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium webpage breached 11 clauses of the U.K ...

Many direct-to-patient (DTP) programs have significantly affected access to medicines, a survey of U.S. | Many direct-to-patient programs have significantly affected access to medicines, a survey of U ...